<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554786</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149B2301</org_study_id>
    <secondary_id>2015-002529-21</secondary_id>
    <nct_id>NCT02554786</nct_id>
  </id_info>
  <brief_title>A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma</brief_title>
  <official_title>A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the efficacy and safety of two different doses of
      QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses
      (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic
      participants as determined by pulmonary function testing, and effects on asthma control
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2015</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">November 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ-7) at Weeks 4, 12, 26 and 52</measure>
    <time_frame>Weeks 4, 12, 26 and 52</time_frame>
    <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FEV1 at Weeks 4 and 12</measure>
    <time_frame>Weeks 4 (Day 30) and 12 (Day 86)</time_frame>
    <description>Pre-dose trough FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Dose FEV1 (5 Minutes-1 Hour)</measure>
    <time_frame>Up to Week 52 (Day 364)</time_frame>
    <description>Post-dose FEV1 measurements were analyzed at 5 minutes, 15 minutes, 30 minutes and 1 hour. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Vital Capacity (FVC)</measure>
    <time_frame>Up to Week 52 (Day 365)</time_frame>
    <description>FVC is the total amount of air exhaled during the FEV test. Trough FVC is defined as average of the two FVC measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Flow (FEF)Between 25% and 75% of FVC (FEF25-75)</measure>
    <time_frame>Up to Week 52 (Day 365)</time_frame>
    <description>FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment</measure>
    <time_frame>Up to Weeks 26 and 52</time_frame>
    <description>PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose). At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Minimal Important Difference (MID) ACQ ≥ 0.5 at Weeks 26 and 52</measure>
    <time_frame>Weeks 26 (Day 183) and 52 (Day 364)</time_frame>
    <description>Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Asthma Symptoms Free Days</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Form Baseline in Percentage of Days With no Daytime Symptoms</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Nights With no Night-time Awakenings</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Form Baseline in Percentage of Mornings With no Symptoms on Awakening</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for mornings with no symptoms on awakening was &quot;Did you have asthma symptoms upon awakening in the morning?&quot; to be answered with &quot;None&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Usage</measure>
    <time_frame>Up to Weeks 26 and 52</time_frame>
    <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. The number of puffs of rescue medication during the past 12 hours is recorded twice (morning/evening) by the participant prior to taking study medication. The mean daily number of puffs of rescue medication use will be calculated for each participant, done separately for morning (night-time), evening (daytime), and daily (night-time plus daytime) rescue medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation by Exacerbation Category</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hospitalization for Asthma Exacerbation</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Asthma Exacerbations by Exacerbation Category</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration in Days of Asthma Exacerbations by Exacerbation Category</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbations</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Permanently Discontinued Study Medication Due to Asthma Exacerbations</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amounts of Systemic Corticosteroids (in Doses) Used to Treat Asthma Exacerbations</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Rescue Medication Free Days</measure>
    <time_frame>Up to Weeks 26 and 52</time_frame>
    <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ)</measure>
    <time_frame>Up to Week 52 (Day 364)</time_frame>
    <description>AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Measured After 26 Weeks of Treatment</measure>
    <time_frame>Week 26</time_frame>
    <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>Approximately up to 56 weeks</time_frame>
    <description>An AE is any untoward medical occurrence (i.e., any unfavorable and unintended sign including abnormal laboratory findings, symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following criteria: is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant, i.e. defined as an event that jeopardizes the participants or may require medical or surgical intervention.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2216</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>QMF149 150/160 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QMF149 150/320 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF 400 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol /fluticasone 50/500 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF 800 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol acetate/Mometasone furoate</intervention_name>
    <arm_group_label>QMF149 150/160 µg</arm_group_label>
    <arm_group_label>QMF149 150/320 µg</arm_group_label>
    <other_name>QMF149</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <arm_group_label>MF 400 µg</arm_group_label>
    <arm_group_label>MF 800 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol xinafoate/fluticasone propionate</intervention_name>
    <arm_group_label>Salmeterol /fluticasone 50/500 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with a diagnosis of asthma, for a period of at least 1 year prior to
             Visit 1 (Screening)

          -  Participants who have used medium or high dose inhaled corticosteroids (ICS) or low
             dose of long acting beta-2 agonist (LABA)/ICS combinations for asthma for at least 3
             months and at stable doses for at least 1 month prior to Visit 1

          -  Participants must have ACQ-7 score ≥ 1.5 at Visit 101 and at Visit 102 (prior to
             double-blind treatment) and qualify for treatment with medium or high dose LABA/ICS

          -  Pre-bronchodilator ≥ 50% Forced expiratory volume in 1 second (FEV1) of &lt; 85 % of the
             predicted normal value for the participants after withholding bronchodilators at both
             Visit 101 and 102, according to American Thoracic Society/European Respiratory Society
             (ATS/ERS) criteria.

          -  Withholding period of bronchodilators prior to spirometry: short acting beta-2 agonist
             (SABA) for ≥ 6 hours and FDC or free combinations of ICS/LABA for ≥ 48 hours, short
             acting anticholinergics (SAMA) for ≥ 8 hours, xanthines &gt;=07 days

          -  A one-time repeat/re-testing of percent predicted FEV1 (prebronchodilator FEV1) is
             allowed at Visit 101 and at Visit 102.

        Spacer devices are permitted for reversibility testing only.

        -Participants who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after
        administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101 All
        participants must perform a reversibility test at Visit 101

        If reversibility is not demonstrated at Visit 101:

          -  Reversibility should be repeated once-

          -  Participants may be permitted to enter the study with historical evidence of
             reversibility that was performed according to ATS/ERS guidelines within 2 years prior
             to Visit 1

          -  Alternatively, participants may be permitted to enter the study with a historical
             positive bronchoprovocation test that was performed within 2 years prior to Visit 1.

        Exclusion Criteria:

          -  Participants who have smoked or inhaled tobacco products within the 6 month period
             prior to Visit 1, or who have a smoking history of greater than 10 pack years. This
             includes use of nicotine inhalers such as e-cigarettes at the time of Visit 1

          -  Participants who have had an asthma attack/exacerbation requiring systemic steroids or
             hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening)

          -  Participants who have ever required intubation for a severe asthma
             attack/exacerbation.

          -  Participants who have a clinical condition which is likely to be worsened by ICS
             administration (e.g. glaucoma, cataract and fragility fractures) who are according to
             investigator's medical judgment at risk participating in the study).

          -  Participants who have had a respiratory tract infection or asthma worsening as
             determined by the investigator within 4 weeks prior to Visit 1 (Screening) or between
             Visit 1 and Visit 102. Participants may be re-screened 4 weeks after recovery from
             their respiratory tract infection or asthma worsening.

          -  Participants with a history of chronic lung diseases other than asthma, including (but
             not limited to) Chronic Obstructive Pulmonary Disease (COPD), sarcoidosis,
             interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and
             active tuberculosis.

          -  Participants with severe narcolepsy and/or insomnia.

          -  Participants who have a clinically significant electrocardiogram (ECG) abnormality at
             Visit 101 (Start of Run- In epoch) and at any time between Visit 101 and Visit 102
             (including unscheduled ECG). ECG evidence of myocardial infarction at Visit 101 (via
             central reader) should be clinically assessed by the investigator with
             supportivedocumentation

          -  Participants with a history of hypersensitivity to lactose, any of the study drugs or
             to similar drugs within the class including untoward reactions to sympathomimetic
             amines or inhaled medication or any component thereof

          -  Participants who have not achieved an acceptable spirometry results at Visit 101 in
             accordance with ATS/ERS criteria for acceptability and repeatability (rescreening
             allowed only once).

        Repeat spirometry may be allowed once in an ad-hoc visit if the spirometry did not qualify
        due to ATS/ERS criteria. If the participant fails the repeat assessment, the participant
        may be rescreened once

          -  Participants on Maintenance Immunotherapy (desensitization) for allergies or less than
             3 months prior to Visit 101 or participants on Maintenance Immunotherapy for more than
             3 months prior to Visit 101 but expected to change throughout the course of the study.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing of study treatment and for 30 days after stopping of study treatment.

          -  Long acting muscarinic antagonist (LAMA) use within 3 months prior to Visit 101
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waldorf</city>
        <state>Maryland</state>
        <zip>20602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747-3322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cortland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <state>BGR</state>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <state>BGR</state>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vidin</city>
        <state>BGR</state>
        <zip>3703</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Troyan</city>
        <zip>5600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varazdin</city>
        <state>HRV</state>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <state>HRV</state>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrinja</city>
        <zip>44250</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zadar</city>
        <zip>23000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beroun</city>
        <state>Czech Republic</state>
        <zip>266 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boskovice</city>
        <state>Czech Republic</state>
        <zip>680 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <state>Czech Republic</state>
        <zip>466 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <state>Czech Republic</state>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurim</city>
        <state>Czech Republic</state>
        <zip>66434</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <state>Czech Republic</state>
        <zip>14800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <state>Czech Republic</state>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varnsdorf</city>
        <state>Czech Republic</state>
        <zip>40747</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <state>CZE</state>
        <zip>709 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <state>CZE</state>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <state>CZE</state>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breclav</city>
        <zip>690 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cesky Krumlov</city>
        <zip>381 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kutna Hora</city>
        <zip>28401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novy Bor</city>
        <zip>47301</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <zip>323 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 8</city>
        <zip>182 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rokycany</city>
        <zip>337 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peine</city>
        <state>Niedersachsen</state>
        <zip>31224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahlen</city>
        <zip>59229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>D-44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boehlen</city>
        <zip>04564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delitzsch</city>
        <zip>04509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dueren</city>
        <zip>52349</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Furstenwalde</city>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hochstadt</city>
        <zip>91315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>D-35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neu Isenburg</city>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuss</city>
        <zip>41462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rheine</city>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rudersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schleswig</city>
        <zip>24837</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwedt</city>
        <zip>16303</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weinheim</city>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad</city>
        <state>Gautemala</state>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <state>GTM</state>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <state>GTM</state>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01057</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1037</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1117</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyor</city>
        <state>HUN</state>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hajdunanas</city>
        <state>HUN</state>
        <zip>4080</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mako</city>
        <state>HUN</state>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <state>HUN</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puspokladany</city>
        <state>HUN</state>
        <zip>4150</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szazhalombatta</city>
        <state>HUN</state>
        <zip>2440</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cegled</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Csorna</city>
        <zip>H-9300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dombovar</city>
        <zip>7200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mosdos</city>
        <zip>7257</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szigetvar</city>
        <zip>7900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390021</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400601</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <zip>160 062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>County Limerick</city>
        <zip>V94 F858</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ichihara-city</city>
        <state>Chiba</state>
        <zip>299-0111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>819-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kasuga-city</city>
        <state>Fukuoka</state>
        <zip>816-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yanagawa-city</city>
        <state>Fukuoka</state>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obihiro-city</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Himeji-city</city>
        <state>Hyogo</state>
        <zip>671-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Himeji-city</city>
        <state>Hyogo</state>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki</state>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atsugi-city</city>
        <state>Kanagawa</state>
        <zip>243-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>255</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>223-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kishiwada-city</city>
        <state>Osaka</state>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka</state>
        <zip>530 0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takatsuki-city</city>
        <state>Osaka</state>
        <zip>569-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyonaka-city</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yao-city</city>
        <state>Osaka</state>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koshigaya-city</city>
        <state>Saitama</state>
        <zip>343-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <state>Shibuya Ku</state>
        <zip>150 0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>103 0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuou-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Setagaya-Ku</city>
        <state>Tokyo</state>
        <zip>157-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima ku</city>
        <state>Tokyo</state>
        <zip>170 0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheongju si</city>
        <state>Chungcheongbuk Do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>26427</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bundang Gu</city>
        <state>Gyeonggi Do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucheon-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho Gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT-48259</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49449</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siauliai</city>
        <zip>LT-76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utena</city>
        <zip>LT-28151</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09108</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <state>POL</state>
        <zip>91-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wejherowo</city>
        <state>POL</state>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aleksandrow Odzki</city>
        <zip>95-070</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Biaystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Inowroclaw</city>
        <zip>88-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40 085</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-741</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <zip>01518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <state>Jud Iasi</state>
        <zip>700732</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Constanta</city>
        <state>Jud. Constanta</state>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <state>Jud.Dolj</state>
        <zip>200341</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <state>ROM</state>
        <zip>12071</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <state>ROM</state>
        <zip>000000</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <state>ROM</state>
        <zip>200712</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deva</city>
        <state>ROM</state>
        <zip>330084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>ROM</state>
        <zip>300298</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arad</city>
        <zip>310013</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bacau</city>
        <zip>600114</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bragadiru</city>
        <zip>077025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braila</city>
        <zip>810003</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasov</city>
        <zip>500051</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>012363</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>050554</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400275</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Codlea</city>
        <zip>505100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramnicu Valcea</city>
        <zip>240564</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suceava</city>
        <zip>720284</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540072</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Penza</city>
        <zip>440067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191180</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>194223</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>196240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavropol</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vologodonsk</city>
        <zip>347382</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beograd</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <state>Slovak Republic</state>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bojnice</city>
        <state>Slovak Republic</state>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>83103</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Humenne</city>
        <state>Slovak Republic</state>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <state>Slovak Republic</state>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skalica</city>
        <state>Slovak Republic</state>
        <zip>90901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <state>Slovak Republic</state>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stropkov</city>
        <state>Slovak Republic</state>
        <zip>09101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surany</city>
        <state>Slovak Republic</state>
        <zip>942 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Velky Meder</city>
        <state>Slovak Republic</state>
        <zip>94201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Námestovo</city>
        <state>Slovensko</state>
        <zip>02901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <state>SVK</state>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cadca</city>
        <zip>022 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ilava</city>
        <zip>1901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarno</city>
        <zip>945 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>077 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <zip>034 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prievidza</city>
        <zip>97101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topolcany</city>
        <zip>95501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berea</city>
        <state>Durban</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belleville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fowey</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liskeard</city>
        <state>Cornwall</state>
        <zip>PL14 3XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torpoint</city>
        <state>Cornwall</state>
        <zip>PL11 2TB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Faringdon</city>
        <state>Oxfordshire</state>
        <zip>SN7 7YU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <state>South Gloucestershire</state>
        <zip>BS37 4AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY5 3LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denbighshire</city>
        <zip>LL181DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC14 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 8AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotherham</city>
        <zip>S65 1DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiltshire</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <results_first_submitted>December 19, 2019</results_first_submitted>
  <results_first_submitted_qc>February 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2020</results_first_posted>
  <disposition_first_submitted>June 3, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 17, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 5, 2019</disposition_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QMF149, Mometasone furoate (MF), asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02554786/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02554786/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in 316 investigative sites in 24 countries from 29 Dec 2015 to 28 Jun 2019.</recruitment_details>
      <pre_assignment_details>3890 participants were screened of which 2216 were randomized to 1 of the 5 treatment groups with a randomization ratio of 1:1:1:1:1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QMF149 150/320 μg</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered once daily (o.d.) via Concept1 inhaler in the evening.</description>
        </group>
        <group group_id="P2">
          <title>QMF149 150/160 μg</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
        </group>
        <group group_id="P3">
          <title>MF 800 μg</title>
          <description>Mometasone furoate (MF) 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
        </group>
        <group group_id="P4">
          <title>MF 400 μg</title>
          <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
        </group>
        <group group_id="P5">
          <title>Salmeterol/Fluticasone 50/500 μg</title>
          <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="439"/>
                <participants group_id="P3" count="442"/>
                <participants group_id="P4" count="444"/>
                <participants group_id="P5" count="446"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="413"/>
                <participants group_id="P3" count="412"/>
                <participants group_id="P4" count="403"/>
                <participants group_id="P5" count="416"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set (RAN) consisted of all participants who were assigned a randomization number, regardless of whether or not they actually received study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>QMF149 150/320 μg</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
        </group>
        <group group_id="B2">
          <title>QMF149 150/160 μg</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
        </group>
        <group group_id="B3">
          <title>MF 800 μg</title>
          <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
        </group>
        <group group_id="B4">
          <title>MF 400 μg</title>
          <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
        </group>
        <group group_id="B5">
          <title>Salmeterol/Fluticasone 50/500 μg</title>
          <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="445"/>
            <count group_id="B2" value="439"/>
            <count group_id="B3" value="442"/>
            <count group_id="B4" value="444"/>
            <count group_id="B5" value="446"/>
            <count group_id="B6" value="2216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="14.56"/>
                    <measurement group_id="B2" value="47.4" spread="14.76"/>
                    <measurement group_id="B3" value="47.5" spread="14.99"/>
                    <measurement group_id="B4" value="48.7" spread="14.98"/>
                    <measurement group_id="B5" value="48.9" spread="14.59"/>
                    <measurement group_id="B6" value="47.9" spread="14.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="272"/>
                    <measurement group_id="B5" value="256"/>
                    <measurement group_id="B6" value="1293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="172"/>
                    <measurement group_id="B5" value="190"/>
                    <measurement group_id="B6" value="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="318"/>
                    <measurement group_id="B4" value="312"/>
                    <measurement group_id="B5" value="305"/>
                    <measurement group_id="B6" value="1559"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="102"/>
                    <measurement group_id="B6" value="493"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic Or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>East Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Southeast Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Russian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="349"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed ethnicity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="242"/>
                    <measurement group_id="B4" value="239"/>
                    <measurement group_id="B5" value="227"/>
                    <measurement group_id="B6" value="1151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26</title>
        <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set (FAS) consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26</title>
          <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>Full Analysis Set (FAS) consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>litre (L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="372"/>
                <count group_id="O4" value="376"/>
                <count group_id="O5" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.383" spread="0.0159"/>
                    <measurement group_id="O2" value="2.387" spread="0.0160"/>
                    <measurement group_id="O3" value="2.250" spread="0.0162"/>
                    <measurement group_id="O4" value="2.176" spread="0.0162"/>
                    <measurement group_id="O5" value="2.346" spread="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least Square mean (LS Mean)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0223</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0224</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.167</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ-7) at Weeks 4, 12, 26 and 52</title>
        <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions.</description>
        <time_frame>Weeks 4, 12, 26 and 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ-7) at Weeks 4, 12, 26 and 52</title>
          <description>The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="431"/>
                <count group_id="O4" value="428"/>
                <count group_id="O5" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="429"/>
                    <count group_id="O4" value="425"/>
                    <count group_id="O5" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.486" spread="0.0337"/>
                    <measurement group_id="O2" value="1.533" spread="0.0338"/>
                    <measurement group_id="O3" value="1.659" spread="0.0338"/>
                    <measurement group_id="O4" value="1.730" spread="0.0337"/>
                    <measurement group_id="O5" value="1.541" spread="0.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="414"/>
                    <count group_id="O3" value="422"/>
                    <count group_id="O4" value="407"/>
                    <count group_id="O5" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.394" spread="0.0347"/>
                    <measurement group_id="O2" value="1.377" spread="0.0348"/>
                    <measurement group_id="O3" value="1.523" spread="0.0348"/>
                    <measurement group_id="O4" value="1.625" spread="0.0350"/>
                    <measurement group_id="O5" value="1.445" spread="0.0345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="405"/>
                    <count group_id="O4" value="393"/>
                    <count group_id="O5" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.267" spread="0.0350"/>
                    <measurement group_id="O2" value="1.261" spread="0.0350"/>
                    <measurement group_id="O3" value="1.439" spread="0.0352"/>
                    <measurement group_id="O4" value="1.509" spread="0.0354"/>
                    <measurement group_id="O5" value="1.322" spread="0.0349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="385"/>
                    <count group_id="O2" value="397"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="377"/>
                    <count group_id="O5" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.231" spread="0.0358"/>
                    <measurement group_id="O2" value="1.183" spread="0.0356"/>
                    <measurement group_id="O3" value="1.373" spread="0.0359"/>
                    <measurement group_id="O4" value="1.449" spread="0.0361"/>
                    <measurement group_id="O5" value="1.221" spread="0.0354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0415</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.254</ci_lower_limit>
            <ci_upper_limit>-0.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0416</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.278</ci_lower_limit>
            <ci_upper_limit>-0.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0414</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.136</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4: The comparison of QMF149 vs. MF was based on combined effects of QMF149 150/160 &amp; 150/320 μg and MF 400 &amp; 800 μg derived by weighting treatment groups equally.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.184</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0294</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.242</ci_lower_limit>
            <ci_upper_limit>-0.127</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.214</ci_lower_limit>
            <ci_upper_limit>-0.044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.248</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0435</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.333</ci_lower_limit>
            <ci_upper_limit>-0.162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.052</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.136</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 12: The comparison of QMF149 vs. MF was based on combined effects of QMF149 150/160 &amp; 150/320 μg and MF 400 &amp; 800 μg derived by weighting treatment groups equally.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0307</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.248</ci_lower_limit>
            <ci_upper_limit>-0.128</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.171</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0437</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.257</ci_lower_limit>
            <ci_upper_limit>-0.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.248</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0439</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.334</ci_lower_limit>
            <ci_upper_limit>-0.162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.214</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0437</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.140</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26: The comparison of QMF149 vs. MF was based on combined effects of QMF149 150/160 &amp; 150/320 μg and MF 400 &amp; 800 μg derived by weighting treatment groups equally.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0310</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.270</ci_lower_limit>
            <ci_upper_limit>-0.149</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0449</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.229</ci_lower_limit>
            <ci_upper_limit>-0.053</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.266</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.354</ci_lower_limit>
            <ci_upper_limit>-0.177</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.824</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0447</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52: The comparison of QMF149 vs. MF was based on combined effects of QMF149 150/160 &amp; 150/320 μg and MF 400 &amp; 800 μg derived by weighting treatment groups equally.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.203</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0318</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.266</ci_lower_limit>
            <ci_upper_limit>-0.141</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 at Week 52</title>
        <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 at Week 52</title>
          <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="364"/>
                <count group_id="O4" value="369"/>
                <count group_id="O5" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.386" spread="0.0168"/>
                    <measurement group_id="O2" value="2.357" spread="0.0167"/>
                    <measurement group_id="O3" value="2.249" spread="0.0170"/>
                    <measurement group_id="O4" value="2.148" spread="0.0170"/>
                    <measurement group_id="O5" value="2.338" spread="0.0167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0235</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0235</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.163</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0234</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose FEV1 at Weeks 4 and 12</title>
        <description>Pre-dose trough FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>Weeks 4 (Day 30) and 12 (Day 86)</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d via Twisthaler® in the evening</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol /Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose FEV1 at Weeks 4 and 12</title>
          <description>Pre-dose trough FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="430"/>
                <count group_id="O4" value="427"/>
                <count group_id="O5" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="430"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="421"/>
                    <count group_id="O4" value="412"/>
                    <count group_id="O5" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.369" spread="0.0141"/>
                    <measurement group_id="O2" value="2.367" spread="0.0142"/>
                    <measurement group_id="O3" value="2.237" spread="0.0143"/>
                    <measurement group_id="O4" value="2.171" spread="0.0143"/>
                    <measurement group_id="O5" value="0.2333" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 86</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                    <count group_id="O2" value="414"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="398"/>
                    <count group_id="O5" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.368" spread="0.0148"/>
                    <measurement group_id="O2" value="2.361" spread="0.0148"/>
                    <measurement group_id="O3" value="2.245" spread="0.0148"/>
                    <measurement group_id="O4" value="2.177" spread="0.0149"/>
                    <measurement group_id="O5" value="2.330" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0193</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.158</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0192</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 86</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 86</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.184</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0202</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.144</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 86</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.063</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Dose FEV1 (5 Minutes-1 Hour)</title>
        <description>Post-dose FEV1 measurements were analyzed at 5 minutes, 15 minutes, 30 minutes and 1 hour. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>Up to Week 52 (Day 364)</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective time point.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Post Dose FEV1 (5 Minutes-1 Hour)</title>
          <description>Post-dose FEV1 measurements were analyzed at 5 minutes, 15 minutes, 30 minutes and 1 hour. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective time point.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="438"/>
                <count group_id="O4" value="438"/>
                <count group_id="O5" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: 5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="426"/>
                    <count group_id="O3" value="429"/>
                    <count group_id="O4" value="432"/>
                    <count group_id="O5" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.279" spread="0.0084"/>
                    <measurement group_id="O2" value="2.270" spread="0.0085"/>
                    <measurement group_id="O3" value="2.138" spread="0.0085"/>
                    <measurement group_id="O4" value="2.118" spread="0.0084"/>
                    <measurement group_id="O5" value="2.224" spread="0.0084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 15 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="434"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="433"/>
                    <count group_id="O5" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.321" spread="0.0088"/>
                    <measurement group_id="O2" value="2.312" spread="0.0089"/>
                    <measurement group_id="O3" value="2.159" spread="0.0089"/>
                    <measurement group_id="O4" value="2.137" spread="0.0089"/>
                    <measurement group_id="O5" value="2.278" spread="0.0088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="438"/>
                    <count group_id="O5" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.338" spread="0.0095"/>
                    <measurement group_id="O2" value="2.326" spread="0.0096"/>
                    <measurement group_id="O3" value="2.162" spread="0.0096"/>
                    <measurement group_id="O4" value="2.141" spread="0.0095"/>
                    <measurement group_id="O5" value="2.310" spread="0.0095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="440"/>
                    <count group_id="O2" value="434"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="438"/>
                    <count group_id="O5" value="442"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.343" spread="0.0100"/>
                    <measurement group_id="O2" value="2.347" spread="0.0101"/>
                    <measurement group_id="O3" value="2.166" spread="0.0101"/>
                    <measurement group_id="O4" value="2.142" spread="0.0100"/>
                    <measurement group_id="O5" value="2.337" spread="0.0100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: 5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="411"/>
                    <count group_id="O5" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.413" spread="0.0142"/>
                    <measurement group_id="O2" value="2.406" spread="0.0144"/>
                    <measurement group_id="O3" value="2.224" spread="0.0145"/>
                    <measurement group_id="O4" value="2.174" spread="0.0145"/>
                    <measurement group_id="O5" value="2.360" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="429"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="421"/>
                    <count group_id="O4" value="412"/>
                    <count group_id="O5" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.432" spread="0.0143"/>
                    <measurement group_id="O2" value="2.426" spread="0.0145"/>
                    <measurement group_id="O3" value="2.238" spread="0.0146"/>
                    <measurement group_id="O4" value="2.174" spread="0.0146"/>
                    <measurement group_id="O5" value="2.389" spread="0.0143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30: 1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="416"/>
                    <count group_id="O3" value="421"/>
                    <count group_id="O4" value="410"/>
                    <count group_id="O5" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.448" spread="0.0145"/>
                    <measurement group_id="O2" value="2.440" spread="0.0146"/>
                    <measurement group_id="O3" value="2.257" spread="0.0147"/>
                    <measurement group_id="O4" value="2.183" spread="0.0148"/>
                    <measurement group_id="O5" value="2.411" spread="0.0144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 86:5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="411"/>
                    <count group_id="O3" value="416"/>
                    <count group_id="O4" value="395"/>
                    <count group_id="O5" value="427"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.411" spread="0.0150"/>
                    <measurement group_id="O2" value="2.409" spread="0.0150"/>
                    <measurement group_id="O3" value="2.248" spread="0.0150"/>
                    <measurement group_id="O4" value="2.178" spread="0.0153"/>
                    <measurement group_id="O5" value="2.356" spread="0.0148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 86: 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="411"/>
                    <count group_id="O3" value="417"/>
                    <count group_id="O4" value="395"/>
                    <count group_id="O5" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.436" spread="0.0149"/>
                    <measurement group_id="O2" value="2.431" spread="0.0149"/>
                    <measurement group_id="O3" value="2.257" spread="0.0149"/>
                    <measurement group_id="O4" value="2.179" spread="0.0152"/>
                    <measurement group_id="O5" value="2.398" spread="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 86:1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="410"/>
                    <count group_id="O3" value="417"/>
                    <count group_id="O4" value="396"/>
                    <count group_id="O5" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.456" spread="0.0151"/>
                    <measurement group_id="O2" value="2.436" spread="0.0151"/>
                    <measurement group_id="O3" value="2.269" spread="0.0151"/>
                    <measurement group_id="O4" value="2.188" spread="0.0154"/>
                    <measurement group_id="O5" value="2.413" spread="0.0149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="404"/>
                    <count group_id="O2" value="399"/>
                    <count group_id="O3" value="400"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.403" spread="0.0160"/>
                    <measurement group_id="O2" value="2.406" spread="0.0161"/>
                    <measurement group_id="O3" value="2.240" spread="0.0162"/>
                    <measurement group_id="O4" value="2.163" spread="0.0164"/>
                    <measurement group_id="O5" value="2.359" spread="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="401"/>
                    <count group_id="O3" value="399"/>
                    <count group_id="O4" value="383"/>
                    <count group_id="O5" value="407"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.426" spread="0.0163"/>
                    <measurement group_id="O2" value="2.427" spread="0.0164"/>
                    <measurement group_id="O3" value="2.250" spread="0.0165"/>
                    <measurement group_id="O4" value="2.168" spread="0.0167"/>
                    <measurement group_id="O5" value="2.386" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="400"/>
                    <count group_id="O3" value="397"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.432" spread="0.0161"/>
                    <measurement group_id="O2" value="2.423" spread="0.0162"/>
                    <measurement group_id="O3" value="2.253" spread="0.0163"/>
                    <measurement group_id="O4" value="2.165" spread="0.0165"/>
                    <measurement group_id="O5" value="2.393" spread="0.0161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364: 5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="380"/>
                    <count group_id="O4" value="374"/>
                    <count group_id="O5" value="403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.384" spread="0.0172"/>
                    <measurement group_id="O2" value="2.379" spread="0.0169"/>
                    <measurement group_id="O3" value="2.245" spread="0.0172"/>
                    <measurement group_id="O4" value="2.130" spread="0.0173"/>
                    <measurement group_id="O5" value="2.358" spread="0.0168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364: 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="377"/>
                    <count group_id="O2" value="393"/>
                    <count group_id="O3" value="379"/>
                    <count group_id="O4" value="373"/>
                    <count group_id="O5" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.408" spread="0.0171"/>
                    <measurement group_id="O2" value="2.399" spread="0.0169"/>
                    <measurement group_id="O3" value="2.253" spread="0.0172"/>
                    <measurement group_id="O4" value="2.135" spread="0.0172"/>
                    <measurement group_id="O5" value="2.377" spread="0.0167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364:1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="393"/>
                    <count group_id="O3" value="379"/>
                    <count group_id="O4" value="375"/>
                    <count group_id="O5" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.414" spread="0.0175"/>
                    <measurement group_id="O2" value="2.390" spread="0.0172"/>
                    <measurement group_id="O3" value="2.251" spread="0.0175"/>
                    <measurement group_id="O4" value="2.128" spread="0.0176"/>
                    <measurement group_id="O5" value="2.383" spread="0.0171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>0.175</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0116</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1: 15 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.162</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1: 15 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0123</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day1: 15 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.068</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.175</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.149</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.053</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1: 1hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.205</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.177</ci_lower_limit>
            <ci_upper_limit>0.232</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 1: 1hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.632</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 30: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.189</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0192</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 30: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.194</ci_lower_limit>
            <ci_upper_limit>0.270</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 30: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0191</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 30: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.194</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.232</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 30: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.253</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.214</ci_lower_limit>
            <ci_upper_limit>0.291</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 30: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0192</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 30: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.190</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0196</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 30: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.258</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0198</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.219</ci_lower_limit>
            <ci_upper_limit>0.296</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 30: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 86: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0204</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 86: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.231</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0206</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.191</ci_lower_limit>
            <ci_upper_limit>0.271</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 86: 5minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0203</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 86: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.180</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0203</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.140</ci_lower_limit>
            <ci_upper_limit>0.219</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 86: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.252</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0205</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.211</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 86: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0202</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 86: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.187</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0205</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.147</ci_lower_limit>
            <ci_upper_limit>0.227</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 86: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.249</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0208</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.208</ci_lower_limit>
            <ci_upper_limit>0.289</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 86: 1hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0205</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 183: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0217</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.121</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 183: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.243</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0219</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.200</ci_lower_limit>
            <ci_upper_limit>0.286</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 183: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0216</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 183: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0222</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.220</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 183: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.259</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0224</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.215</ci_lower_limit>
            <ci_upper_limit>0.303</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 183: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 183: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.180</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0219</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 183: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.259</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0222</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.215</ci_lower_limit>
            <ci_upper_limit>0.302</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 183: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0218</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 364: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0229</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 364: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.249</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0228</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.205</ci_lower_limit>
            <ci_upper_limit>0.294</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 364: 5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.244</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0227</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 364: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0228</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 364: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.264</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0227</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.219</ci_lower_limit>
            <ci_upper_limit>0.308</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 364: 30 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 364: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0234</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.117</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 364: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.262</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0232</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.216</ci_lower_limit>
            <ci_upper_limit>0.308</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 364: 1 hour</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.031</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0231</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Vital Capacity (FVC)</title>
        <description>FVC is the total amount of air exhaled during the FEV test. Trough FVC is defined as average of the two FVC measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
        <time_frame>Up to Week 52 (Day 365)</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity (FVC)</title>
          <description>FVC is the total amount of air exhaled during the FEV test. Trough FVC is defined as average of the two FVC measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="436"/>
                <count group_id="O4" value="441"/>
                <count group_id="O5" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="432"/>
                    <count group_id="O2" value="430"/>
                    <count group_id="O3" value="410"/>
                    <count group_id="O4" value="435"/>
                    <count group_id="O5" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.342" spread="0.0173"/>
                    <measurement group_id="O2" value="3.342" spread="0.0174"/>
                    <measurement group_id="O3" value="3.256" spread="0.0177"/>
                    <measurement group_id="O4" value="3.203" spread="0.0173"/>
                    <measurement group_id="O5" value="3.344" spread="0.0176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 184</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="372"/>
                    <count group_id="O4" value="376"/>
                    <count group_id="O5" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.372" spread="0.0179"/>
                    <measurement group_id="O2" value="3.387" spread="0.0180"/>
                    <measurement group_id="O3" value="3.322" spread="0.0183"/>
                    <measurement group_id="O4" value="3.246" spread="0.0182"/>
                    <measurement group_id="O5" value="3.355" spread="0.0180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="383"/>
                    <count group_id="O3" value="365"/>
                    <count group_id="O4" value="369"/>
                    <count group_id="O5" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.394" spread="0.0182"/>
                    <measurement group_id="O2" value="3.364" spread="0.0181"/>
                    <measurement group_id="O3" value="3.319" spread="0.0184"/>
                    <measurement group_id="O4" value="3.218" spread="0.0183"/>
                    <measurement group_id="O5" value="3.358" spread="0.0182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0237</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0235</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.927</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0237</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 184</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0246</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 184</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0246</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 184</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0244</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0249</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.146</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Flow (FEF)Between 25% and 75% of FVC (FEF25-75)</title>
        <description>FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
        <time_frame>Up to Week 52 (Day 365)</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Flow (FEF)Between 25% and 75% of FVC (FEF25-75)</title>
          <description>FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents the number of participants with data at respective visit.</population>
          <units>Litres/second (L/s)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="433"/>
                <count group_id="O3" value="436"/>
                <count group_id="O4" value="441"/>
                <count group_id="O5" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="432"/>
                    <count group_id="O2" value="430"/>
                    <count group_id="O3" value="410"/>
                    <count group_id="O4" value="435"/>
                    <count group_id="O5" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.644" spread="0.0186"/>
                    <measurement group_id="O2" value="1.617" spread="0.0187"/>
                    <measurement group_id="O3" value="1.455" spread="0.0191"/>
                    <measurement group_id="O4" value="1.406" spread="0.0186"/>
                    <measurement group_id="O5" value="1.662" spread="0.0189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 184</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="389"/>
                    <count group_id="O3" value="372"/>
                    <count group_id="O4" value="376"/>
                    <count group_id="O5" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.775" spread="0.0249"/>
                    <measurement group_id="O2" value="1.738" spread="0.0250"/>
                    <measurement group_id="O3" value="1.546" spread="0.0253"/>
                    <measurement group_id="O4" value="1.473" spread="0.0254"/>
                    <measurement group_id="O5" value="1.692" spread="0.0250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="383"/>
                    <count group_id="O3" value="365"/>
                    <count group_id="O4" value="369"/>
                    <count group_id="O5" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.745" spread="0.0259"/>
                    <measurement group_id="O2" value="1.686" spread="0.0257"/>
                    <measurement group_id="O3" value="1.530" spread="0.0261"/>
                    <measurement group_id="O4" value="1.440" spread="0.0261"/>
                    <measurement group_id="O5" value="1.692" spread="0.0258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.189</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0253</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.475</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0252</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.067</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 184</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.228</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0345</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.296</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 184</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0346</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.197</ci_lower_limit>
            <ci_upper_limit>0.333</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 184</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0343</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.215</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0358</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.145</ci_lower_limit>
            <ci_upper_limit>0.285</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.246</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0357</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.176</ci_lower_limit>
            <ci_upper_limit>0.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 365</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0356</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment</title>
        <description>PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose). At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.</description>
        <time_frame>Up to Weeks 26 and 52</time_frame>
        <population>Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study medication. n represents tthe number of participants with data at respective visit.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment</title>
          <description>PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose). At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.</description>
          <population>Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study medication. n represents tthe number of participants with data at respective visit.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26: Mean morning PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="418"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="430"/>
                    <count group_id="O4" value="422"/>
                    <count group_id="O5" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="2.15"/>
                    <measurement group_id="O2" value="38.1" spread="2.15"/>
                    <measurement group_id="O3" value="12.8" spread="2.13"/>
                    <measurement group_id="O4" value="5.9" spread="2.14"/>
                    <measurement group_id="O5" value="29.1" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26:Mean evening PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="419"/>
                    <count group_id="O5" value="423"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="2.05"/>
                    <measurement group_id="O2" value="30.4" spread="2.04"/>
                    <measurement group_id="O3" value="7.7" spread="2.04"/>
                    <measurement group_id="O4" value="0.0" spread="2.05"/>
                    <measurement group_id="O5" value="23.9" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Mean morning PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="422"/>
                    <count group_id="O5" value="424"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" spread="2.24"/>
                    <measurement group_id="O2" value="36.9" spread="2.22"/>
                    <measurement group_id="O3" value="13.4" spread="2.21"/>
                    <measurement group_id="O4" value="6.7" spread="2.22"/>
                    <measurement group_id="O5" value="28.3" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Mean evening PEF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="416"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="424"/>
                    <count group_id="O4" value="418"/>
                    <count group_id="O5" value="422"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="2.14"/>
                    <measurement group_id="O2" value="28.7" spread="2.13"/>
                    <measurement group_id="O3" value="7.4" spread="2.13"/>
                    <measurement group_id="O4" value="-0.3" spread="2.14"/>
                    <measurement group_id="O5" value="22.1" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26: Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Linear Mixed Model (LMM)</method>
            <param_type>LS Mean</param_type>
            <param_value>29.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.8</ci_lower_limit>
            <ci_upper_limit>35.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26: Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>32.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.4</ci_lower_limit>
            <ci_upper_limit>38.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26: Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>13.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>19.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 26: Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>24.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.3</ci_lower_limit>
            <ci_upper_limit>30.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 26: Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>30.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.8</ci_lower_limit>
            <ci_upper_limit>35.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 26: Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>8.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.1</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52: Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>28.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.7</ci_lower_limit>
            <ci_upper_limit>34.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52: Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>30.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.2</ci_lower_limit>
            <ci_upper_limit>36.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52: Mean morning PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>13.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.7</ci_lower_limit>
            <ci_upper_limit>19.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52: Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>23.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.0</ci_lower_limit>
            <ci_upper_limit>29.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52: Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>29.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.3</ci_lower_limit>
            <ci_upper_limit>34.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 52: Mean evening PEF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>9.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the Minimal Important Difference (MID) ACQ ≥ 0.5 at Weeks 26 and 52</title>
        <description>Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions</description>
        <time_frame>Weeks 26 (Day 183) and 52 (Day 364)</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents number of participants with data at the respective visit.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the Minimal Important Difference (MID) ACQ ≥ 0.5 at Weeks 26 and 52</title>
          <description>Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means &gt; 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means &lt; 50% of predicted FEV1). The total score was calculated as the mean of all questions</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents number of participants with data at the respective visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="405"/>
                    <count group_id="O4" value="393"/>
                    <count group_id="O5" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4"/>
                    <measurement group_id="O2" value="76.2"/>
                    <measurement group_id="O3" value="72.3"/>
                    <measurement group_id="O4" value="66.9"/>
                    <measurement group_id="O5" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="385"/>
                    <count group_id="O2" value="397"/>
                    <count group_id="O3" value="387"/>
                    <count group_id="O4" value="377"/>
                    <count group_id="O5" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7"/>
                    <measurement group_id="O2" value="82.1"/>
                    <measurement group_id="O3" value="73.6"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.746</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 364</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 364</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.58</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 364</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>Logistic regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Asthma Symptoms Free Days</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Asthma Symptoms Free Days</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="402"/>
                <count group_id="O3" value="408"/>
                <count group_id="O4" value="404"/>
                <count group_id="O5" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="1.72"/>
                    <measurement group_id="O2" value="28.4" spread="1.72"/>
                    <measurement group_id="O3" value="22.5" spread="1.72"/>
                    <measurement group_id="O4" value="19.3" spread="1.72"/>
                    <measurement group_id="O5" value="24.9" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Linear Mixed Model (LMM)</method>
            <param_type>LS Mean</param_type>
            <param_value>5.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>9.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Form Baseline in Percentage of Days With no Daytime Symptoms</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Form Baseline in Percentage of Days With no Daytime Symptoms</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="420"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="419"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="1.69"/>
                    <measurement group_id="O2" value="28.0" spread="1.69"/>
                    <measurement group_id="O3" value="23.0" spread="1.68"/>
                    <measurement group_id="O4" value="20.0" spread="1.69"/>
                    <measurement group_id="O5" value="24.8" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>5.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>8.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Nights With no Night-time Awakenings</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Nights With no Night-time Awakenings</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was &quot;How did you sleep last night?&quot; had to be answered with &quot;I did not wake up because of any breathing problems&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>percentage of nights</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="420"/>
                <count group_id="O3" value="428"/>
                <count group_id="O4" value="422"/>
                <count group_id="O5" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="1.28"/>
                    <measurement group_id="O2" value="16.4" spread="1.27"/>
                    <measurement group_id="O3" value="14.2" spread="1.27"/>
                    <measurement group_id="O4" value="12.5" spread="1.27"/>
                    <measurement group_id="O5" value="16.1" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.104</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Form Baseline in Percentage of Mornings With no Symptoms on Awakening</title>
        <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for mornings with no symptoms on awakening was &quot;Did you have asthma symptoms upon awakening in the morning?&quot; to be answered with &quot;None&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Form Baseline in Percentage of Mornings With no Symptoms on Awakening</title>
          <description>All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for mornings with no symptoms on awakening was &quot;Did you have asthma symptoms upon awakening in the morning?&quot; to be answered with &quot;None&quot; with scores from 0 (no problem)-4 (very severe problems).</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>percentage of mornings</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="420"/>
                <count group_id="O3" value="428"/>
                <count group_id="O4" value="422"/>
                <count group_id="O5" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="1.66"/>
                    <measurement group_id="O2" value="22.9" spread="1.65"/>
                    <measurement group_id="O3" value="19.1" spread="1.65"/>
                    <measurement group_id="O4" value="14.1" spread="1.65"/>
                    <measurement group_id="O5" value="20.7" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>6.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>8.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Usage</title>
        <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. The number of puffs of rescue medication during the past 12 hours is recorded twice (morning/evening) by the participant prior to taking study medication. The mean daily number of puffs of rescue medication use will be calculated for each participant, done separately for morning (night-time), evening (daytime), and daily (night-time plus daytime) rescue medication use</description>
        <time_frame>Up to Weeks 26 and 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents number of participants included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Usage</title>
          <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. The number of puffs of rescue medication during the past 12 hours is recorded twice (morning/evening) by the participant prior to taking study medication. The mean daily number of puffs of rescue medication use will be calculated for each participant, done separately for morning (night-time), evening (daytime), and daily (night-time plus daytime) rescue medication use</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents number of participants included in the analysis.</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1-26 Mean night-time number of puffs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="418"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="430"/>
                    <count group_id="O4" value="422"/>
                    <count group_id="O5" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.028"/>
                    <measurement group_id="O2" value="-0.27" spread="0.028"/>
                    <measurement group_id="O3" value="-0.26" spread="0.028"/>
                    <measurement group_id="O4" value="-0.19" spread="0.028"/>
                    <measurement group_id="O5" value="-0.34" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week1-26 Mean daytime number of puffs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="419"/>
                    <count group_id="O5" value="424"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.035"/>
                    <measurement group_id="O2" value="-0.46" spread="0.035"/>
                    <measurement group_id="O3" value="-0.38" spread="0.035"/>
                    <measurement group_id="O4" value="-0.34" spread="0.035"/>
                    <measurement group_id="O5" value="-0.53" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week1-26 Mean daily number of puffs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="428"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="428"/>
                    <count group_id="O5" value="432"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.059"/>
                    <measurement group_id="O2" value="-0.73" spread="0.059"/>
                    <measurement group_id="O3" value="-0.65" spread="0.059"/>
                    <measurement group_id="O4" value="-0.53" spread="0.059"/>
                    <measurement group_id="O5" value="-0.87" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week1-52 Mean night-time number of puffs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="422"/>
                    <count group_id="O5" value="424"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.029"/>
                    <measurement group_id="O2" value="-0.30" spread="0.029"/>
                    <measurement group_id="O3" value="-0.29" spread="0.028"/>
                    <measurement group_id="O4" value="-0.20" spread="0.029"/>
                    <measurement group_id="O5" value="-0.35" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-52 Mean daytime number of puffs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="416"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="419"/>
                    <count group_id="O5" value="423"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.035"/>
                    <measurement group_id="O2" value="-0.51" spread="0.035"/>
                    <measurement group_id="O3" value="-0.43" spread="0.035"/>
                    <measurement group_id="O4" value="-0.36" spread="0.035"/>
                    <measurement group_id="O5" value="-0.55" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-52 Mean daily number of puffs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="428"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="428"/>
                    <count group_id="O5" value="432"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.060"/>
                    <measurement group_id="O2" value="-0.80" spread="0.060"/>
                    <measurement group_id="O3" value="-0.72" spread="0.060"/>
                    <measurement group_id="O4" value="-0.56" spread="0.060"/>
                    <measurement group_id="O5" value="-0.91" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week1-26 Mean night-time number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean night-time number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean night-time number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean daytime number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean daytime number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean daytime number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.425</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean daily number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean daily number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 1-26 Mean daily number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean night-time number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean night-time number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean night-time number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean daytime number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean daytime number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean daytime number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.384</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean daily number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean daily number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 1-52 Mean daily number of puffs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.0" lower_limit="2" upper_limit="389"/>
                    <measurement group_id="O2" value="366.0" lower_limit="1" upper_limit="429"/>
                    <measurement group_id="O3" value="366.0" lower_limit="2" upper_limit="390"/>
                    <measurement group_id="O4" value="364.0" lower_limit="2" upper_limit="402"/>
                    <measurement group_id="O5" value="366.0" lower_limit="2" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367" lower_limit="2" upper_limit="389"/>
                    <measurement group_id="O2" value="366" lower_limit="1" upper_limit="429"/>
                    <measurement group_id="O3" value="366" lower_limit="2" upper_limit="390"/>
                    <measurement group_id="O4" value="366" lower_limit="2" upper_limit="402"/>
                    <measurement group_id="O5" value="366" lower_limit="3" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate or severe) asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.0" lower_limit="2" upper_limit="389"/>
                    <measurement group_id="O2" value="366.0" lower_limit="1" upper_limit="429"/>
                    <measurement group_id="O3" value="364.5" lower_limit="2" upper_limit="390"/>
                    <measurement group_id="O4" value="306.0" lower_limit="2" upper_limit="402"/>
                    <measurement group_id="O5" value="365.0" lower_limit="2" upper_limit="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.209</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Hospitalization for Asthma Exacerbation</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalization for Asthma Exacerbation</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.0" lower_limit="2" upper_limit="389"/>
                    <measurement group_id="O2" value="367.0" lower_limit="1" upper_limit="429"/>
                    <measurement group_id="O3" value="367.0" lower_limit="2" upper_limit="390"/>
                    <measurement group_id="O4" value="366.0" lower_limit="2" upper_limit="402"/>
                    <measurement group_id="O5" value="367.0" lower_limit="3" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.337</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.063</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.599</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Asthma Exacerbations by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Asthma Exacerbations by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>exacerbations per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.20" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.27" lower_limit="0.21" upper_limit="0.34"/>
                    <measurement group_id="O3" value="0.39" lower_limit="0.32" upper_limit="0.48"/>
                    <measurement group_id="O4" value="0.56" lower_limit="0.46" upper_limit="0.68"/>
                    <measurement group_id="O5" value="0.27" lower_limit="0.22" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.09" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.10" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.18" lower_limit="0.13" upper_limit="0.23"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.23" upper_limit="0.38"/>
                    <measurement group_id="O5" value="0.14" lower_limit="0.10" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate, severe) asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.41" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.40" upper_limit="0.59"/>
                    <measurement group_id="O3" value="0.74" lower_limit="0.62" upper_limit="0.88"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.89" upper_limit="1.24"/>
                    <measurement group_id="O5" value="0.52" lower_limit="0.43" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.669</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.597</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.681</p_value>
            <method>Generalized linear model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration in Days of Asthma Exacerbations by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participant in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration in Days of Asthma Exacerbations by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS consisted of all participant in the RAN set who received at least one dose of study medication.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="10.60"/>
                    <measurement group_id="O2" value="3.0" spread="12.53"/>
                    <measurement group_id="O3" value="3.7" spread="11.40"/>
                    <measurement group_id="O4" value="5.8" spread="13.98"/>
                    <measurement group_id="O5" value="3.1" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="6.02"/>
                    <measurement group_id="O2" value="1.7" spread="8.48"/>
                    <measurement group_id="O3" value="1.7" spread="6.07"/>
                    <measurement group_id="O4" value="3.2" spread="9.16"/>
                    <measurement group_id="O5" value="1.9" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All(mild, moderate,severe) asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="18.81"/>
                    <measurement group_id="O2" value="5.0" spread="17.55"/>
                    <measurement group_id="O3" value="6.9" spread="22.96"/>
                    <measurement group_id="O4" value="10.1" spread="25.15"/>
                    <measurement group_id="O5" value="5.1" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Moderate or severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Severe Asthma Exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe Asthma Exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Severe asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All(mild, moderate, severe) Asthma Exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) Asthma Exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Van Elteren Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All (mild, moderate, severe) asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all patients in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS consisted of all patients in the RAN set who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="16.9"/>
                    <measurement group_id="O3" value="26.1"/>
                    <measurement group_id="O4" value="32.5"/>
                    <measurement group_id="O5" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="20.1"/>
                    <measurement group_id="O5" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="16.5"/>
                    <measurement group_id="O5" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="17.5"/>
                    <measurement group_id="O4" value="19.6"/>
                    <measurement group_id="O5" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All (mild, moderate, severe) asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="36.1"/>
                    <measurement group_id="O4" value="44.5"/>
                    <measurement group_id="O5" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbations</title>
        <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol /Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbations</title>
          <description>The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.0" lower_limit="2" upper_limit="389"/>
                    <measurement group_id="O2" value="367.0" lower_limit="1" upper_limit="429"/>
                    <measurement group_id="O3" value="367.0" lower_limit="2" upper_limit="390"/>
                    <measurement group_id="O4" value="366.0" lower_limit="2" upper_limit="402"/>
                    <measurement group_id="O5" value="367.0" lower_limit="3" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.222</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.992</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit_na_comment>The upper limit of CI could not be calculated due to low number of participants with asthma exacerbation.</ci_upper_limit_na_comment>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.618</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>6.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Permanently Discontinued Study Medication Due to Asthma Exacerbations</title>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Permanently Discontinued Study Medication Due to Asthma Exacerbations</title>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amounts of Systemic Corticosteroids (in Doses) Used to Treat Asthma Exacerbations</title>
        <description>The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amounts of Systemic Corticosteroids (in Doses) Used to Treat Asthma Exacerbations</title>
          <description>The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="136.92"/>
                    <measurement group_id="O2" value="29.9" spread="124.98"/>
                    <measurement group_id="O3" value="28.0" spread="95.18"/>
                    <measurement group_id="O4" value="47.8" spread="139.98"/>
                    <measurement group_id="O5" value="26.9" spread="114.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Rescue Medication Free Days</title>
        <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.</description>
        <time_frame>Up to Weeks 26 and 52</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents number of participants with data at respective visit.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d via Concept1 inhaler in the evening</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d via Twisthaler® in the evening</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol /Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Rescue Medication Free Days</title>
          <description>All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication. n represents number of participants with data at respective visit.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 1-26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="416"/>
                    <count group_id="O3" value="424"/>
                    <count group_id="O4" value="414"/>
                    <count group_id="O5" value="421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="1.53"/>
                    <measurement group_id="O2" value="27.4" spread="1.53"/>
                    <measurement group_id="O3" value="21.4" spread="1.52"/>
                    <measurement group_id="O4" value="19.1" spread="1.53"/>
                    <measurement group_id="O5" value="27.4" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="416"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="414"/>
                    <count group_id="O5" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="1.55"/>
                    <measurement group_id="O2" value="29.4" spread="1.54"/>
                    <measurement group_id="O3" value="23.5" spread="1.54"/>
                    <measurement group_id="O4" value="20.8" spread="1.54"/>
                    <measurement group_id="O5" value="28.8" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Weeks 1-26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>10.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.2</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Weeks 1-26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>8.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.3</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Weeks 1-26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Weeks 1-52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>9.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Weeks 1-52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>8.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.7</ci_lower_limit>
            <ci_upper_limit>12.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Weeks 1-52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>LMM</method>
            <param_type>LS Mean</param_type>
            <param_value>4.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ)</title>
        <description>AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items)</description>
        <time_frame>Up to Week 52 (Day 364)</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ)</title>
          <description>AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items)</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="431"/>
                <count group_id="O4" value="428"/>
                <count group_id="O5" value="438"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="430"/>
                    <count group_id="O4" value="425"/>
                    <count group_id="O5" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.560" spread="0.0327"/>
                    <measurement group_id="O2" value="5.498" spread="0.0328"/>
                    <measurement group_id="O3" value="5.413" spread="0.0326"/>
                    <measurement group_id="O4" value="5.374" spread="0.0327"/>
                    <measurement group_id="O5" value="5.515" spread="0.0324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 86</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="416"/>
                    <count group_id="O3" value="422"/>
                    <count group_id="O4" value="406"/>
                    <count group_id="O5" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.618" spread="0.0356"/>
                    <measurement group_id="O2" value="5.629" spread="0.0357"/>
                    <measurement group_id="O3" value="5.564" spread="0.0355"/>
                    <measurement group_id="O4" value="5.510" spread="0.0359"/>
                    <measurement group_id="O5" value="5.592" spread="0.0352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="405"/>
                    <count group_id="O4" value="393"/>
                    <count group_id="O5" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.724" spread="0.0372"/>
                    <measurement group_id="O2" value="5.738" spread="0.0372"/>
                    <measurement group_id="O3" value="5.598" spread="0.0372"/>
                    <measurement group_id="O4" value="5.581" spread="0.0376"/>
                    <measurement group_id="O5" value="5.639" spread="0.0369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="395"/>
                    <count group_id="O3" value="388"/>
                    <count group_id="O4" value="385"/>
                    <count group_id="O5" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.761" spread="0.0383"/>
                    <measurement group_id="O2" value="5.781" spread="0.0382"/>
                    <measurement group_id="O3" value="5.689" spread="0.0383"/>
                    <measurement group_id="O4" value="5.614" spread="0.0386"/>
                    <measurement group_id="O5" value="5.700" spread="0.0378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="397"/>
                    <count group_id="O3" value="389"/>
                    <count group_id="O4" value="378"/>
                    <count group_id="O5" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.783" spread="0.0391"/>
                    <measurement group_id="O2" value="5.832" spread="0.0388"/>
                    <measurement group_id="O3" value="5.705" spread="0.0389"/>
                    <measurement group_id="O4" value="5.641" spread="0.0394"/>
                    <measurement group_id="O5" value="5.742" spread="0.0384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0462</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.237</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0464</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 30</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 86</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0503</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 86</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0507</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 86</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.598</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0501</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.072</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0526</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0529</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0525</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 254</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.188</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0542</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.178</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 254</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0543</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.274</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 254</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.258</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0538</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 364</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0552</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 364</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0553</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.299</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 364</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.455</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0548</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.067</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Measured After 26 Weeks of Treatment</title>
        <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
        <time_frame>Week 26</time_frame>
        <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Measured After 26 Weeks of Treatment</title>
          <description>Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.</description>
          <population>FAS consisted of all participants in the RAN set who received at least one dose of study medication.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="372"/>
                <count group_id="O4" value="376"/>
                <count group_id="O5" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.383" spread="0.0159"/>
                    <measurement group_id="O2" value="2.387" spread="0.0160"/>
                    <measurement group_id="O3" value="2.250" spread="0.0162"/>
                    <measurement group_id="O4" value="2.176" spread="0.0162"/>
                    <measurement group_id="O5" value="2.346" spread="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>QMF 150/320 was considered non-inferior to S/F 50/500 if the lower bound of the 95% CI was above the non-inferiority margin of -90 mL and was considered superior if the lower bound of the 95% CI was &gt; 0. The p-value is for null-hypothesis testing.</non_inferiority_desc>
            <p_value>0.101</p_value>
            <method>MMRM</method>
            <param_type>LS Mean</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0222</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes</title>
        <description>A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>Safety Set consisted of all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes</title>
          <description>A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.</description>
          <population>Safety Set consisted of all participants who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.8"/>
                    <measurement group_id="O5" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
        <description>An AE is any untoward medical occurrence (i.e., any unfavorable and unintended sign including abnormal laboratory findings, symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following criteria: is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant, i.e. defined as an event that jeopardizes the participants or may require medical or surgical intervention.</description>
        <time_frame>Approximately up to 56 weeks</time_frame>
        <population>Safety Set consisted of all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 150/320 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O2">
            <title>QMF149 150/160 μg</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
          </group>
          <group group_id="O3">
            <title>MF 800 μg</title>
            <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
          </group>
          <group group_id="O4">
            <title>MF 400 μg</title>
            <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
          </group>
          <group group_id="O5">
            <title>Salmeterol/Fluticasone 50/500 μg</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
          <description>An AE is any untoward medical occurrence (i.e., any unfavorable and unintended sign including abnormal laboratory findings, symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following criteria: is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant, i.e. defined as an event that jeopardizes the participants or may require medical or surgical intervention.</description>
          <population>Safety Set consisted of all participants who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="443"/>
                <count group_id="O5" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events(AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6"/>
                    <measurement group_id="O2" value="66.8"/>
                    <measurement group_id="O3" value="70.0"/>
                    <measurement group_id="O4" value="72.2"/>
                    <measurement group_id="O5" value="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events(SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events: From first dose up to 30 days post last dose (approximately 56 weeks) Other adverse events: From first dose up to 7 days post last dose (approximately 53 weeks)</time_frame>
      <desc>The Safety Set consisted of all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>QMF 150/320</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
        </group>
        <group group_id="E2">
          <title>QMF 150/160</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered o.d. via Concept1 inhaler in the evening.</description>
        </group>
        <group group_id="E3">
          <title>MF 800</title>
          <description>MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.</description>
        </group>
        <group group_id="E4">
          <title>MF 400</title>
          <description>MF 400 μg was delivered o.d. via Twisthaler® in the evening.</description>
        </group>
        <group group_id="E5">
          <title>S/F 50/500</title>
          <description>Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal deposits</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Complicated appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental device ingestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Vertebral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cervix enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Chronic rhinosinusitis with nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="263" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="290" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="239" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="194" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="137" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

